-+ 0.00%
-+ 0.00%
-+ 0.00%

UBS Maintains Buy on Altimmune, Lowers Price Target to $24

Benzinga·08/13/2025 15:51:40
Listen to the news
UBS analyst Eliana Merle maintains Altimmune (NASDAQ:ALT) with a Buy and lowers the price target from $26 to $24.